How Caerus fulfilled the specific research needs of a drug development company to reach critical proof of concept faster
The directive: The client was developing a series of PD-1/PD-L1 inhibitor peptide therapeutics for cancer immunotherapy. The problem: Screening of several potential drug candidates through in vitro methods revealed promising candidates that needed to be tested in an in vivo tumor model to evaluate anti-tumor activity to obtain critical proof of concept for investors. […]
How Caerus utilized a non-conventional development strategy for an anti-human fractalkine receptor antibody
The directive: Caerus was tasked with the development of antibodies specific to human CX3CR1 (a.k.a., fractalkine receptor) as a therapeutic for inflammatory diseases. The problem: CX3CR1, also known as fractalkine receptor, is a 7-transmembrane GPCR protein. CX3CR1 is also a highly conserved protein, with 67% identity between mouse and human sequences. This hydrophobic protein […]
